Obatoclax mesylate: Pharmacology and potential for therapy of hematological neoplasms

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 363-373

  Joudeh, Jamal ^a   Claxton, David ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Bcl 2; Leukemia; Lymphoma; Targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; BH3 PROTEIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DEATH RECEPTOR 4; DEXAMETHASONE; ENTINOSTAT; FAS ANTIBODY; FLUDARABINE; FLUOROURACIL; ISOSORBIDE; MELPHALAN; NAVITOCLAX; OBATOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB; SORAFENIB; SURVIVIN; THAPSIGARGIN; TUNICAMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ATAXIA; BILE DUCT CARCINOMA; BLAST CELL CRISIS; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COUGHING; CYTOTOXICITY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DYSPNEA; ESOPHAGUS CANCER; EUPHORIA; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG SMALL CELL CANCER; LYMPHOMA; MAINTENANCE THERAPY; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA AND VOMITING; NEOPLASM; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES;

EID: 84856813420     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.652302     Document Type: Review

References (48)

1. Yip KW, Reed JC, Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27:6398-406
2. Kim I, Xu W, Reed JC, et al. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7:1013-30
3. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86
4. Youle RJ, Strasser A, Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59
5. Nuessler V, Stotzer O, Gullis E, et al. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 1999;13:1864-72 (Pubitemid 29535273)
6. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92 (Pubitemid 29535275)
7. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl 1):S149-57
8. Khaw SL, Huang DC, Roberts AW. BH3-mimetics: the solution to chemoresistance? Leuk Lymphoma 2009;50:1069-72
9. Ketley NJ, Allen PD, Kelsey SM, et al. Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 2000;14:620-8 (Pubitemid 30195452)
10. Stahnke K, Mohr A, Liu J, et al. Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis. Apoptosis 2004;9:457-65 (Pubitemid 38987582)
11. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19 (Pubitemid 23259742)
12. Merino R, Ding L, Veis DJ, et al. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994;13:683-91 (Pubitemid 24050683)
13. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430:199-205
14. Shore GC, Viallet J. Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 2005;2005:226-30
15. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104:19512-17
16. Pepper C, Hoy T, Bentley DP, et al. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-8 (Pubitemid 27401947)
17. Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22:1712-20
18. Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413-20
19. Koh GS, Jiang N, Dong DF, et al. BH3-Mimetics, ABT-737 and obatoclax, work synergistically to induce cell death in leukemic cell lines. ASH Annual Meeting Abstracts. Blood 2010;116:1850
20. Wei Y, Kadia T, Tong W, et al. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 2010;16:3923-32
21. Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010;1:e76
22. Urtishak KA, Wang LS, Harvey R, et al. Infant acute lymphoblastic leukemias are pan-sensitive to obatoclax across molecular/cytogenetic subtypes, especially MLL-ENL, and gene expression profiles determine obatoclax IC50: a report on the Children's Oncology Group (COG) P9407 trial. ASH Annual Meeting Abstracts. Blood 2010;116:2757
23. Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-9 (Pubitemid 46743414)
24. Hernandez-Ilizaliturri F, Tsio PC, Campagna R, et al. Obatoclax and bortezomib therapy results in disruption of the p53-mediated apoptosis/autophagy pathway and is associated with potent synergistic anti-tumor activity against rituximab-chemotherapy-sensitive and-resistant B-Cell lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114:288
25. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, et al. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 2011;10:2792-805
26. Brem EA, Thudium K, Khubchandani S, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and-resistant lymphomas. Br J Haematol 2011;153:599-611
27. Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17
28. Trudel S, Li ZH, Rauw J, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-8 (Pubitemid 46890566)
29. Huang S, Okumura K, Sinicrope FA, et al. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 2009;15:150-9
30. Smoot RL, Blechacz BR, Werneburg NW, et al. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 2010;70:1960-9
31. Pan J, Cheng C, Verstovsek S, et al. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010;293:167-74
32. Jiang CC, Wroblewski D, Yang F, et al. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia (New York) 2009;11:945-55
33. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-301.
34. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299-305
35. Hwang JJ, Kuruvilla J, Mendelson D, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010;16:4038-45
36. Goy A, Ford P, Feldman T, et al. A Phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. ASH Annual Meeting Abstracts. Blood 2007;110:2569
37. Parikh SA, Kantarjian H, Schimmer A, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leukoc 2010;10:285-9
38. A. Chiappori MTSMMMJSLBRSQSCHJRDSSMSB. Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC) [abstract No: e13531]. 2011
39. Paik PK, Rudin CM, Brown A, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010;66:1079-85
40. Roberts AW, Brown J, Seymour JF, et al. An ongoing phase 1 study of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2008;112:3177
41. Wilson WH, O'Connor O, Czuczman MS, et al. Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. ASH Annual Meeting Abstracts. Blood 2008;112:2108
42. Roberts AW, Seymour JF, Brown JR, et al. An ongoing phase 1/2a study of ABT-263; Pharmacokinetics (PK), safety and anti-tumor activity in patients (pts) with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2009;114:883
43. Balakrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-53
44. Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009;15:3172-6
45. McGregor N, Patel L, Craig M, et al. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem 2010;110:1187-94
46. Deng J, Carlson N, Takeyama K, et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-85. (Pubitemid 47199122)
47. Brem EA, Thudium K, Khubchandani S, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and-resistant lymphomas. Br J Haematol 2011;153:599-611
48. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906-16